Yangcheng Evening News reporter Lu Zhilin，Intern Wu Yaqin Report: According to foreign media reports，The world's largest pharmaceutical dealer Pfizer said，Planning to sell or stripped its two major business departments of animal health and nutritional products，It is intended to use the income income to repurchase stocks and develop new drugs。Yesterday，The relevant person in My stake betting appcharge Stake Sports Bettingof the Chinese area of ​​Pfizer told the reporter of Yangcheng Evening News，American companies have indeed planned to peel away from the above two businesses。

 

Price or up to 23.5 billion US dollars

 

According to Pfizer's plan，The two major businesses preparing to sell or strip this time are animal health and nutritional products。The annual sales of these two businesses reached 5.5 billion US dollars，8%of the total revenue of Pfizer。CEO Aan Ride said，Since these two businesses are significantly different from the core business of Pfizer，These two businesses may maximize value outside the company after stripping。 It is reported，Pfizer's animal health care business last year's sales revenue reached 3.6 billion US dollars，It is one of the world's largest animal health product manufacturers。Analyst estimates that this business value can reach 100-16 billion US dollars。In the United States Pharmaceutical Merchant Corporation and another multinational pharmaceutical company Novartis, which had just been approved by the European Union on Thursday, may be buyers of this business。

 

The nutritional business of the same divestitudes My stake betting appof the divestiture business stake sports betting apprevenue last year was $ 1.9 billion。Analyst estimates that the price of this business may reach $ 6-75 billion。Because Wyeth's infant formula milk powder may also be splitted，Therefore, analysts think，Mead Johnson、Abbott、Danone、Nestlé, etc. will be potential buyers。Total two，Price from $ 16 to 23.5 billion。

 

Pfizer said，and other schemes are determined，The transaction will be completed within 12-24 months in the following。

 

Pfizer said，After peeling away from the above two major departments，It is intended to use the income income to repurchase stocks and develop new drugs。

 

For the past 10 years，Pfizer invested 70 billion US dollars in the research and development field，But only two annual sales successfully exceeded the $ 1 billion of drugs。2000-2010，Pfizer has 9 new drugs approved through FDA，The number of new drugs is ranked third among major pharmaceutical companies。But most of these new drugs are not called seats。More importantly，Pfizer's best -selling cholesterol lowering cholesterol medicine Lipcao will lose patent protection rights in November this year。Last year，This drug creates My stake betting appa sales of up to $ 10.7 stake sports betting appbillion。Pfizer estimates，If the new drug cannot make up for the sales loss of Lipcao，The company's sales in the next two years will decline up to 8.3%。

 

Big Machal Expand Series Dipping

 

January 26, 2009，Pfizer announced the acquisition of Wyeth through cash and stocks，The total transaction price reaches $ 68 billion，Step in the global pharmaceutical "one brother" throne。At that time, some analysts thought，Pfizer's acquisition of Wyeth aims to obtain Wyeth's biopharmaceutical technology and vaccine business，To promote the growth of Pfizer's sales。

 

After that，Pfizer integrates all its business into two major groups，Biopharmaceuticals and Diversity Department。Where，Diversified departments include animal health、Capsule products、Consumer health and nutritional products。

 

February this year，Pfizer's new CEO Aan Ride issued a signal to split the giant company for spin -off in his first performance report。

 

In April this year，Pfizer has announced that it will sell its capsule business department CAPSUGEL，Cash transaction scale reaches 2.4 billion US dollars，Become the beginning of the Pfizer Series Dipping Action。